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Abstract
Inherited leukodystrophies are a group of neurological disorders with significant morbidity and 
mortality. Children and their families can experience lengthy diagnostic odysseys; however, there 
is no data on the charges related to testing for diagnosis in leukodystrophy patients, compared to 
approaches using next-generation sequencing (NGS). Our objective was to determine charges 
related to the determination of diagnosis, and overall yield of diagnostic testing, for 
leukodystrophy patients. We determined and quantified all inpatient and outpatient lab testing, 
including brain MRIs, obtained for the purpose of diagnosis, in a retrospective population cohort 
of children with inherited leukodystrophies. Each patient had average charges of $8,231 (range 
$543–26,437) for diagnostic testing. Overall charges related to diagnosis for the entire cohort was 
$526,794. A final etiological diagnosis was determined in 34% of patients. In those in whom a 
specific diagnosis was determined, average time to diagnosis was 1.4 years. If NGS on the entire 
cohort had been performed instead, charges would have been ~$359,600 (at $5,800/patient). 
Alternatively, a two-tier approach consisting of first, biochemical testing (serum very-long chain 
fatty acids and leukocyte lysosomal enzyme testing), and then with NGS for remaining 
undiagnosed patients, would have resulted in total cohort charges of $361,309. We have 
determined the charges directly associated with diagnostic testing in a population cohort of 
children with leukodystrophy. We conclude that appropriately incorporating NGS into diagnostic 
algorithms could lower charges; reduce time to diagnosis; and reduce amount of testing.
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Inherited leukodystrophies are a group of genetically diverse diseases with more than 30% 
mortality by age 8 years [Bonkowsky et al., 2010; Raymond et al., 2011]. Clinical trials and 
therapy development are inhibited by low rates of diagnosis [Schiffmann and Van Der 
Knaap, 2009; Bonkowsky et al., 2010]. Next-generation sequencing (NGS) approaches, 
including whole exome, whole genome, and gene panels, offer the potential to improve 
diagnostic yield and reduce the time and cost to diagnosis [Yang et al., 2013]. There is no 
comparative data, however, on the charges related to testing for diagnosis in leukodystrophy 
patients using current standards of practice.
Our objective was to determine charges related to the determination of diagnosis and overall 
yield of diagnostic testing for leukodystrophy patients. This information would guide 
options for diagnostic algorithms incorporating NGS in the leukodystrophies, and more 
broadly can inform processes to reduce the diagnostic odyssey in patients with rare diseases.
 METHODS
The Institutional Review Boards of the University of Utah and Intermountain Healthcare 
(IH) approved this study. The study was a retrospective population cohort collected from a 
9-year period at Primary Children’s Hospital (PCH) and the University of Utah Pediatric 
Neurology Clinic, with a minimum additional 4 years of follow-up. All charges related to 
testing for the purpose of diagnosis were collected, including both in- and out-patient testing 
and brain MRIs. We determined, both manually and by computer search, all lab and 
radiology testing related to diagnosis, including brain MRIs performed after the initial MRI 
performed at presentation. Tests included general and disease screening labs; as well as 
disease-specific testing (for example, respectively: blood chemistry, hemoglobin; leukocyte 
lysosomal enzymes, chromosome karyotype; very long chain fatty acids, Pelizaeus–
Merzbacher gene testing). Tests related to clinical patient care (such as monitoring of drug 
levels) and professional fees were not included. The initial MRI was not included since it 
formed the basis of the inclusion criteria we used. Charges for each test were only included 
for the first instance of that test being obtained. However, we did include charges for repeat 
MRIs. PCH is part of IH, and complete charge data was extracted for each patient from the 
electronic data warehouse and were standardized to 2013 constant U.S. dollars [Nelson et 
al., 2013].
 RESULTS
From 2002–2010, all patients presenting with an apparent inherited leukodystrophy were 
identified and followed through June 2014 using our previous criteria [Bonkowsky et al., 
2010]. The cohort consisted of 62 leukodystrophy patients (Table I); siblings or relatives of 
known leukodystrophy patients were excluded. Each patient had average charges of $8,231 
(range $543–26,437) for diagnostic testing. Overall charges related to diagnosis for the 
entire cohort was $526,794. A final etiological diagnosis was determined in 34% of patients. 
In those in whom a specific diagnosis was determined, average elapsed time to diagnosis 
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was 1.4 years; higher charges and an increased number of tests were associated with 
increasing time to diagnosis (Fig. 1).
 DISCUSSION
We have determined the charges directly associated with diagnostic testing in a population 
cohort of children with leukodystrophy. Charges reflect the end-costs experienced by 
patients and families. While charges vary significantly from institution to institution, and are 
dependent on a variety of financial circumstances that are often not directly related to the 
cost of providing the test, we decided to use charges because it is most reflective of what 
most families and clinicians are familiar with; and what insurance companies commonly 
deal with. Further, information about diagnosis charges can be most easily compared to the 
charges for NGS.
Conservatively assuming a similar rate of diagnostic yield using NGS, charges for NGS on 
the entire cohort would have been ~$359,600 (at $5,800/patient) [Ambry Genetics]. 
Alternatively, a two-tier approach could consist of first, biochemical testing (serum very-
long chain fatty acids and leukocyte lysosomal enzyme testing) for treatable 
leukodystrophies (for X-linked adrenoleukodystrophy and for lysosomal disorders), and then 
with NGS for remaining undiagnosed patients. In this two-tier approach, the first-tier would 
have charges of $42,309, and the second tier charges would be $319,000; for total cohort 
charges of $361,309. Turnaround time for NGS can be as few as 12 weeks, which is 
substantially shorter than the average time to diagnosis we found, but is longer than 
biochemical testing for adrenoleukodystrophy and lysosomal disorders.
Limitations of our work are that it was a single center, and consisted of retrospectively 
collected data. In addition, since the cohort was relatively small, ordering preferences of a 
few physicians could affect the costs and limit generalizability. However, the group of 
pediatric neurologists caring for these children consists of over 12 physicians; and the ability 
to longitudinally track all diagnostic charges are unique strengths of the cohort and database 
used.
We conclude that the advantages of appropriately incorporating NGS into diagnostic 
algorithms may include lower charges; reduced time to diagnosis; and reduced amount of 
testing including reducing repeat MRIs and associated sedations. In addition, with 
improving NGS there is potential for higher diagnosis yield. Our study provides novel 
insight into the charges associated with the diagnostic odyssey, and how that compares to 
charges of NGS. Recently, another group has also shown that NGS appears to have lower 
costs compared to a traditional diagnostic route in children with neurodevelopmental 
disorders (Soden et al., 2014). However, to our knowledge our study and that of Soden et al. 
are the only publications with direct information on the charges associated with diagnosis. 
The detailed information we have determined on the charges and diagnosis rates from the 
diagnostic odyssey provide important information that can be used to improve patient 
diagnosis, management, and care.
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Average charges per patient (y-axis, ^marks) and average number of tests (circles), based on 
time to diagnosis (x-axis).
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TABLE I









Native American 1 (2%)
Diagnosis
Unknown 41 (66%)
Krabbe disease 2 (3%)
Mitochondrial 2 (3%)




Average (range) $8,231 ($543–26,437)
Average per test cost (range) $531 ($7–7,930)
a
Other diagnoses: 2q24.3 syndrome, 4H syndrome, del17p13.3, 18q-syndrome, 46, XY dup(9) (q21.1q22.31), Aicardi–Goutieres, Batten, FG 
syndrome, Gaucher type II, Metachromatic leukodystrophy, Sandhoff, Tay-Sachs, TUBB4a, X-linked Adrenoleukodystrophy, Vanishing White 
Matter.
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